Skip to main content

Neuraxis, INC

corporate_fare Company Profile

Neuraxis, INC

NRXS·NYSE·Industrial Applications And Services·CIK 0001933567

NeurAxis, Inc. is a first-to-market growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company has several indications in the market and additional clinical trials of Percutaneous Electrical Nerve Field Stimulation (PENFS) underway in multiple pediatric and adult conditions, focused on unmet GI healthcare needs in children and adults. Its proprietary IB-Stim therapy is based on PENFS technology developed internally by the Company. The company's first product, IB-Stim, is a PENFS technology intended for use in patients 8 years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. IB-Stim is a US FDA Class II medical device that has received regulatory clearances: IB-Stim (DEN180057, 2019; K252024, 2025), under the regulation name of "non-implanted nerve stimulator for functional abdominal pain relief." The second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient's ability to expel contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension. RED is intended for use in a clinical setting by trained health care providers in adult populations. In May 2025, NASPGHAN (North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition) published functional abdominal pain guidelines listing PENFS as the only FDA-approved or FDA-cleared treatment in the guidelines to be recommended.

Neuraxis, INC (NYSE:NRXS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 1 item for NRXS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Recent SEC coverage for NRXS spans 10-Q.

Recent high-impact activity:

  • NeurAxis Q3 Sales Jump 150% to $2.0M, But Going Concern Warning Persists

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.57M
Net Income
-$7.8M
Diluted EPS
-$0.95
Op. Cash Flow
-$6.43M
Free Cash Flow
-$6.46M
Gross Profit
$3.01M
Operating Income
-$7.83M
Cash & Equivalents
$4.97M
Debt / Equity
0.00×
Net Margin
-218.5%
Shares Outstanding
10.65M sh
Source: 10-K · filed 2026-03-19 · accession 0001493152-26-011505

Short Interest & Short Volume

4.37 days to cover

FINRA reported short interest of 455,871 shares in NRXS as of the October 30, 2026 settlement, a 10.4% increase from the prior period — about 4.4 days to cover at its recent average daily volume. On November 20, 2026, 40.5% of NRXS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)455,871 shares as of October 30, 2026
Change vs prior period▲ 10.4%
Days to cover4.37 at avg daily volume of 104,420
Daily short volume (FINRA facilities)40.5% of 64,058 shares on November 20, 2026
5-day average short volume32.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$4.2 -0.47% today
52-week range · as of 2026-11-09 $2.21 – $9.33
Market cap
$59.9M
Volume
151.8K (0.8× avg)
3-mo avg 180.9K
Live data · 2026-11-21 06:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NRXS - Latest Insights

NRXS
Nov 09, 2026, 7:01 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $6.24
Real-time Price: $4.20 info
Change: -$2.04 (-33%) info
Market Cap: $59.895M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets